Coronavirus: €117 million granted for treatments and diagnostics through the Innovative Medicines Initiative#

May 12, 2020

The Commission announced that 8 large-scale research projects, aimed at developing treatments and diagnostics for the coronavirus, were selected in a fast-track call for proposals, launched in March by the Innovative Medicines Initiative (IMI), a public-private partnership.

In order to fund a larger number of high-quality proposals, the Commission increased its commitment to €72 million (up from the originally planned €45 million) from Horizon 2020, the EU's research and innovation programme.

Read more.


The Innovative Medicines Initiative (IMI) is a public-private partnership between the European Commission and the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Its aim is to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need.

Imprint Privacy policy « This page (revision-3) was last changed on Tuesday, 9. June 2020, 11:39 by Kaiser Dana
  • operated by